The QualityStocks Daily Tuesday, October 13th, 2020

Today's Top 3 Investment Newsletters

QualityStocks (EWLL) +100.00%

Tip.us (AEMD) +33.11%

StreetInsider (ISWH) +21.32%

The QualityStocks Daily Stock List

Abraxas Petroleum Corporation (AXAS)

Stocktwits, Zacks, Streetwise Reports, Digital Market News, Invest Chronicle, Invest Million, Market Screener, MarketBeat, Seeking Alpha, Nasdaq, Investing.com, Annual Reports, TMX.com, Stockhouse, Business Insider, Equities.com, MacroTrends, The Street, ETF.com, News Daemon, EarningsCast, Businesswire, PLSX.com, OilandGas360, The Globe and Mail, MarketWatch, Netcials, Finbox, Fintel, GuruFocus, Finviz, DBT News, Morningstar, Stocklight, and StockNews reported earlier on Abraxas Petroleum Corporation (AXAS), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Abraxas Petroleum Corporation is a crude oil and natural gas exploration and production company listed on the Nasdaq Global Select Market (NasdaqGS). Abraxas has operations across the Rocky Mountains and Permian Basin. The Company concentrates mainly on the development of conventional and unconventional resources in its primary operating areas in the Rocky Mountains, South Texas, Powder River Basin and Permian Basin. Abraxas Petroleum has its corporate headquarters in San Antonio, Texas.

An independent energy enterprise, fundamentally, Abraxas Petroleum engages in the acquisition, exploration, exploitation, development, and production of oil and gas properties in the United States. The Company’s business model centers on assets with high working interest; operational & infrastructure control; low geologic risk; strong full cycle ROR; and low risk exploitable upside using its proven operating expertise.

This past August, Abraxas Petroleum announced that its Board of Directors has determined to renew the strategic alternatives review announced last October and led by Petrie Partners, LLC (Petrie). Petrie’s Mr. Jon Hughes and Mr. Richard Moss will lead the engagement.

Mr. Bob Watson, Abraxas Petroleum Chief Executive Officer, said, "Petrie has been a great partner for Abraxas in the past. Now that we have successfully amended our agreements with Angelo Gordon and our banks, we look forward to working with Petrie to examine ways to optimize value. Our strong, concentrated asset bases in the Delaware and Williston Basins, as well as our excellent hedge book, position Abraxas for success on a standalone basis and also make us an attractive transaction partner."

In addition, in August, Abraxas Petroleum announced that it completed the final elements of its recent refinancing transactions. As disclosed in Abraxas’ Form 8-K filed on August 13, 2020 with the Securities and Exchange Commission (SEC), the Company issued a Warrant to an affiliate of Angelo Gordon (collectively, AG) granting AG the right to purchase up to 33,445,792 shares of Abraxas Petroleum common stock for a purchase price of $.01 per share, at any time during the next five years.

Abraxas Petroleum Corporation (AXAS), closed Tuesday's trading session at $0.1547, off by 2.8876%, on 6,969,844 volume with 00 trades. The average volume for the last 3 months is 7,635,961 and the stock's 52-week low/high is $0.090000003/$0.550000011.

Adriatic Metals PLC (ADMLF)

OTC Markets, Stock Target Advisor, Stock News Now, MarketWatch, Proactive Investors, Fintel, Investing.com, Market Screener, Musthinsider, The Assay, Stockhouse, Famous Finds, TeleTrader, StocksCafe, TipRanks, Wallet Investor, CEO.ca, Newsfilecorp, Dividend.com, London Stock Exchange, Stockwatch, Morningstar, Seeking Alpha, Junior Mining Network, MarketBeat, Dividend Investor, GuruFocus, YCharts, and TradingView reported beforehand on Adriatic Metals PLC (ADMLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Adriatic Metals PLC, by way of its subsidiary, Eastern Mining d.o.o Sarajevo, engages in the mineral exploration business in Bosnia and Herzegovina. The Company explores for zinc, lead, barite, barium sulfate, silver, gold, and copper deposits. Incorporated in 2017, Adriatic Metals is headquartered in Cheltenham, the United Kingdom (UK). The Company lists on the OTC Markets.

Adriatic Metals holds a 100 percent interest in the Vareš Project situated in the Federation of Bosnia and Herzegovina. This is an advanced polymetallic project leveraged to precious and base metal exposure. It is a high grade resource with first-class metallurgy. It is a high margin, high return, low capex (capital expenditure) Project.

The economically viable Vareš Project comprises two high grade polymetallic deposits. These are the Rupice and Veovača deposits. Regarding the Rupice high grade polymetallic deposit, it has a Maiden JORC 2012 Resource of 9.4Mt – 80 percent of the Mineral Resource is in the Indicated Resources category. Mineralization remains open in all directions and highest grade intercepts to date exceed 58m at 58.9 percent ZnEq or 27.0 g/t AuEq.

Furthermore, the Vareš Project neighbors Tier-1 deposits. It has a well defined permitting process. Pertaining to the 2020 Exploration Programme, the Project has a growing resource inventory and wide-ranging data to support new concession applications. The Vareš Project is surrounded by established infrastructure and major discoveries. It is well positioned in central Europe with extensive access to rail networks linking European smelters and the seaborne market.

Concerning the Veovača deposit, it is a Brownfield Mine with growth potential. It has an updated JORC 2012 Mineral Resource of 7.4Mt. It previously produced zinc, lead, and barite concentrate between 1983 and 1987. Drilling at Veovača has added gold and silver into the entirety of the Mineral Resource estimate. Resources begin at the surface and currently extend down to depths of 200 meters.

Last week, Tethyan Resource Corp. (TSXV: TETH) announced the successful completion of its earlier announced business combination with Adriatic Metals, pursuant to which Adriatic Metals has acquired all of the common shares of Tethyan Resource via a court approved Plan of Arrangement. With this Arrangement, Tethyan Resource shareholders will receive 0.166 of one ordinary share of Adriatic Metals for each common share of Tethyan they hold.

Tethyan Resource Corp. is a precious and base metals mineral exploration company. Tethyan is centered on the Tethyan Metallogenic Belt in Eastern Europe, primarily Serbia.

Adriatic Metals PLC (ADMLF), closed Tuesday's trading session at $1.645, even for the day, on 5 volume with 1 trade. The average volume for the last 3 months is 26,521 and the stock's 52-week low/high is $0.50999999/$2.19000005.

Mandalay Resources Corporation (MNDJF)

The Prospector News, Proactive Investors, FX Empire, GlobeNewswire, Market Screener, hot Stocked, Mining Capital, Dividend Investor, Business Insider, TradingView, Newswire, TMXmoney, MarketBeat, Morningstar, Stockwatch, Junior Mining Network, Wallmine, OTC Markets, Northern Miner, Central Charts, and Wallet Investor reported on Mandalay Resources Corporation (MNDJF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Mandalay Resources Corporation has producing assets in Australia and Sweden, and care and maintenance and development projects in Chile. A natural resource company, it is concentrating on boosting production at its gold and antimony operation in Australia, and gold production from its operation in Sweden to produce near-term cash flow. The Company’s mission is to create shareholder value through the acquisition of undervalued assets that can become quickly cash generative, self fund exploration, establish and maintain high operating margins, and return cash to shareholders.

Incorporated in 1997 and listed on the OTC Markets Group’s OTCQB, Mandalay Resources is based in Toronto, Ontario. The Company operates the 100 percent-owned Costerfield gold-antimony mine in Victoria, Australia. It purchased the mine on December 1, 2009, from Western Coal.

Mandalay Resources acquired 100 percent interest in the Björkdal (Birch Valley) gold mine in September 2014, when it purchased 100 percent of Elgin Mining. Björkdal is located in northern Sweden, one of the best mining jurisdictions globally. Björkdal produces gold from a combined open pit and underground operation with roughly 60 percent of plant feed presently delivered from the underground.

In August, Mandalay Resources announced its financial results for the quarter ended June 30, 2020. For Q2 2020, the Company generated Revenue of $42.3 million, Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $21.3 million, and Adjusted Net Income of $7.6 million, or $0.08 Income per Share.

Mr. Dominic Duffy, President and Chief Executive Officer of Mandalay Resources, said, “Mandalay’s strong second quarter financial performance was driven by another all-time record in quarterly adjusted EBITDA at Costerfield of $15.4 million, surpassing the $13.9 million set last quarter. The Company’s excellent consolidated financial performance was the result of another excellent operational quarter at Costerfield and improving production from Björkdal, coupled with a rise in gold prices.”

Mandalay Resources Corporation (MNDJF), closed Tuesday's trading session at $1.219, up 4.8602%, on 11,100 volume with 7 trades. The average volume for the last 3 months is 11,050 and the stock's 52-week low/high is $0.382099986/$1.64999997.

Modern Meat, Inc. (SUVRF)

OTC Markets, The Deep Dive, Vegconomist, MarketWatch, The Globe and Mail, Seeking Alpha, Wallet Investor, Nasdaq, Stockwatch, The CSE, Newsfilecorp, Morningstar, InvestorsHub, Stockhouse, TradingView, GuruFocus, CEO.ca, and Market Screener reported previously on Modern Meat, Inc. (SUVRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Modern Meat, Inc. is a premier plant-based food manufacturer listed on the OTC Markets. The Company focuses on providing consumers nutritious and sustainable meat alternatives without sacrificing taste. Its corporate mission is to change the way food is produced and consumed for the benefit of people, animals, and the environment by using only natural 100 percent plant-based ingredients. Modern Meat has its head office in Vancouver, British Columbia.

The Company offers a portfolio of plant-based meat products. All of Modern Meat’s products are Soy, Gluten, Nut and GMO (Genetically Modified Organism) free. In addition, they are made with no artificial preservatives or additives. Products include Modern Burger, Modern Crumble (Eggplant Crumble), Modern ‘Crab’ Cakes, Modern Meatballs, and Modern Sauces.

In late September, Modern Meat announced that it intends to expand into the United States market. It is evaluating a list of potential acquisition targets. Since listing on the Canadian Stock Exchange (CSE), Modern Meat has been targeting strategic Mergers & Acquisitions (M&A) opportunities, and also internal growth expansion projects. The Company will specifically look to team-up with strong vegan brands that have a broad distribution network and management that aligns with the core principals of Modern Meat.

Last week, Modern Meat announced that it signed a Letter of Intent (LOI) to acquire brands from JDW Distributors LLC (JDW). Acquiring these brands from JDW will introduce a strong sales and distribution network. JDW has been focusing on selling healthy, gourmet foods for 16 years, starting their own line of vegan brands such as the popular Snacks from the Sun® Popped Potato Crisps and Sunflower Chips and Sunsations® Fruit Jellies, the last three years.

Additionally, last week, Modern Meat announced that it sold out of its products for 15 consecutive weeks to retailers and direct to consumer sales. It has been pleased with its initial launch of its line of Modern Burger, Crumble, Meatball, Crab Cake, and sauces. The Company is seeing demand for its product surpass its present production capacity that is leading to the continuous sell outs. As earlier announced, Modern Meat is in the process of expanding its production capacity (Press Release of August 28, 2020).

Modern Meat, Inc. (SUVRF), closed Tuesday's trading session at $2.5437, off by 7.1642%, on 1,644 volume with 7 trades. The average volume for the last 3 months is 4,153 and the stock's 52-week low/high is $0.920000016/$3.43646001.

POET Technologies, Inc. (POETF)

NetworkNewsWire, Zacks, Simply Wall St, Pinnacle Digest, Financial Buzz, Newsfilecorp, Barchart, Dividend Investor, MacroTrends, Agoracom, OTC Markets, Findata, Nasdaq, Proactive Investors, Stockhouse, Market Screener, GuruFocus, last10k, InvestorsHub, Morningstar, Investors Hangout, Wallet Investor, EE Journal Daily, Seeking Alpha, GlobeNewswire, Analyst Ratings, MarketBeat, YCharts, and MarketWatch reported beforehand on POET Technologies, Inc. (POETF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

POET Technologies, Inc. is a design and development company. It provides integration solutions based on the POET Optical Interposer™. This is a novel platform that enables the seamless integration of electronic and photonic devices into a single multi-chip module utilizing advanced wafer-level semiconductor manufacturing techniques and packaging methods. POET Technologies is headquartered in Toronto, Ontario, with operations in Allentown, Pennsylvania and Singapore. The Company’s shares trade on the OTC Markets Group’s OTCQX.

POET Technologies’ Optical Interposer eliminates costly components and labor-intensive assembly, alignment, burn-in and testing methods used in conventional photonics. The cost-efficient integration scheme and scalability of the POET Optical Interposer brings value to any device or system that integrates electronics and photonics. This includes some of the highest growth areas of computing, for example Artificial Intelligence (AI), the Internet of Things (IoT), autonomous vehicles, and high-speed networking for cloud service providers and data centers.

The POET Optical Interposer provides maximum flexibility and scalability. Both electronic and photonic devices are fabricated into the layers of the Optical Interposer at wafer-level. This eliminates active alignment and enables high-speed communication among all devices. Substituting devices or changing form factors is done with minimal design changes to the platform allowing Optical Interposer-based solutions to span many product generations and a wide variety of applications.

The POET Optical Interposer comprises layers of materials built on a standard semiconductor wafer of any size, using standard semiconductor (CMOS) processes. The bottom layers include the high-speed metal traces found in electronic interposers. The top-most layers incorporate waveguides that guide and focus light, other passive devices (such as filters and gratings) and features that enable the accurate placement and integration of active devices.

Last month, POET Technologies announced that it signed a development and supply agreement with a top European optical systems company with worldwide operations for a 400G data center application. This contract includes a nominal amount of Non-Recurring Engineering (NRE) funding to design optical engines based on the POET Optical Interposer for a 400G application, along with a Purchase Order for initial production units. The customer is a foremost provider of optical networking systems for data center and enterprise applications.

POET Technologies, Inc. (POETF), closed Tuesday's trading session at $0.43, up 0.584795%, on 18,197 volume with 4 trades. The average volume for the last 3 months is 64,730 and the stock's 52-week low/high is $0.16854/$0.524999976.

StrikePoint Gold, Inc. (STKXF)

OTC Markets, Streetwise Reports, Beat Penny Stocks, Mining News North, Penny Picks, Junior Mining Network, 24hgold, Newswire.ca, Geology for Investors, TMXmoney, ValueTheMarkets, Northern Miner, Stock of the Week, Stock Day Media, 4-Traders, Resource World, InvestorsHub, Seeking Alpha, Simply Wall St, InvestorX, Pennystocks.news, Smart Stock Trading Strategies, Stock Market Watch, Stockwatch, YCharts, Wallet Investor, PR Newswire, Investing News, Stockhouse, Nasdaq, The Prospector News, TradingView, Barchart, GlobeNewswire, Dividend Investor, Make Penny Stocks Great Again, and Morningstar reported earlier on StrikePoint Gold, Inc. (STKXF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

StrikePoint Gold, Inc. is a gold exploration company centered on building high-grade precious metals resources in Canada. It controls two advanced stage exploration assets in British Columbia’s Golden Triangle. These are the past-producing high-grade silver Porter Project and the high-grade gold property Willoughby, which is adjacent to Red Mountain. Established in 1982, StrikePoint Gold is based in Vancouver, British Columbia. The Company lists on the OTC Markets Group’s OTCQB.

The high grade silver Porter Idaho Property is in the above-mentioned Golden Triangle northwest British Columbia. The Project is adjacent to the town of Stewart, and is serviced by year-round paved highways from Terrace, Prince George, and Vancouver. The Golden Triangle is home to a number of historic and operating mines, and also advanced exploration projects.

StrikePoint Gold’s Willoughby Property is also in the Golden Triangle northwest British Columbia. Historic work at the Willoughby Property includes 119 diamond drill holes between 1989 and 1996 totalling 12,302 meters. Furthermore, the Company owns a portfolio of gold properties in the Yukon. These include the Pluto Project, the Mahtin Project, as well as the Golden Oly Project.

In September, StrikePoint Gold provided an update on its 2020 drilling and surface exploration programs on its 100 percent-owned high-grade Willoughby gold-silver Property and Porter Silver Property in the prolific Golden Triangle. With assays pending for the Phase I drilling program from Willoughby, forthcoming work will center on the past-producing high-grade Porter Silver Project.

The chief goals of the 2020 exploration program at the Willoughby gold-silver property have been to improve continuity of high-grade and to test broad zones of disseminated gold and silver mineralization encountered in earlier drilling and surface sampling. Surface exploration started on July 29, 2020 and drilling commenced on August 10, 2020.

At the high-grade Porter Silver Property, the emphasis of the 2020 exploration season will be linking the two-past-producing high-grade silver mines on the property: the Silverado (northwest) and Prosperity/Porter Idaho (southeast) mines, which outcrop 2,000 meters apart on the opposite sides of Mount Rainey, overlooking the town of Stewart, British Columbia. Forthcoming work will include exploration for new veins that have been identified outside of the historic resources and past producing areas.

Last week, StrikePoint Gold announced that closed its earlier announced non-brokered private placement offering of units of the Company raising $3,235,500 through the sale of 21,570,005 Units at a price of $0.15 per Unit. The proceeds of the Placement will be used to fund StrikePoint's exploration activities on its existing mineral property portfolio and general working capital.

StrikePoint Gold, Inc. (STKXF), closed Tuesday's trading session at $0.1544, off by 10.4408%, on 359,790 volume with 98 trades. The average volume for the last 3 months is 377,202 and the stock's 52-week low/high is $0.0107/$0.212999999.

Top Strike Resources Corp. (TPPRF)

Street Insider, OTC Markets, InvestorX, StocksCafe, GuruFocus, Smarter Analyst, Midas Letter, Stockwatch, Mining and Energy, CannabisFN, TradingView, Analyst Ratings, Dividend Investor, Morningstar, Newswire.ca, Wallet Investor, MarketWatch, The Globe and Mail, Barchart, Nasdaq, PR Newswire, TipRanks, News Break, Stockhouse, Dividend.com, Global Banking and Finance, GlobeNewswire, Seeking Alpha, CEO.ca, Simply Wall St, and BOE Report reported earlier on Top Strike Resources Corp. (TPPRF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Top Strike Resources Corp. d.b.a. "Vencanna Ventures" is working to be a go-to capital provider for early-stage worldwide cannabis initiatives with a concentration on strong management operating in State compliant jurisdictions with barriers to entry. It operates as a merchant capital firm and provides capital for early-stage international cannabis initiatives, including State compliant opportunities in the USA.

The Company previously went by the name Colossal Resources Corp. It changed its name to Top Strike Resources Corp. in December of 2012. Top Strike Resources has its head office in Calgary, Alberta. The Company lists on the OTC Markets Group’s OTCQB.

On September 24, 2018, the Corporation announced the completion of a recapitalization financing, the appointment of a new management team and Board of Directors and start of trading on the CSE. The transactions transitioned the Corporation from an oil and gas issuer to a merchant capital firm, rebranded as "Vencanna Ventures".

As of July 31, 2020, 64 percent of the Corporation's Assets and 100 percent of Other Income was directly related to U.S. cannabis activities. As of September 29, 2020, a significant portion of the Corporation's business was derived from material ancillary involvement in U.S. cannabis-related activities.

Top Strike Resources d.b.a. Vencanna Ventures aims to provide capital, liquidity, and expertise to early stage jurisdictionally compliant cannabis initiatives thus providing its investors with a high growth cannabis investment strategy. The Company is centered on creating shareholder value through building a diversified portfolio of early stage transformative assets across the United States and beyond.

Vencanna Ventures is targeting opportunities with high potential returns (3 to 5x ROI (Return on Investment) within 2 to 5 years). It is taking advantage of its experience to provide exposure to investments in the high growth, developing worldwide cannabis industry. Its strategy is to source at or near cash flow positive opportunities with low upfront capital outlays.

Vencanna Ventures has operating experience throughout the value chain. This includes cultivation, processing, product placement, as well as distribution experience. In addition, its team has more than 100 years of combined corporate finance, capital markets, and direct investing experience. Vencanna has a large and growing network across North America within industry, regulatory, buy side, and sell side contacts.

Top Strike Resources Corp. (TPPRF), closed Tuesday's trading session at $0.01, even for the day, on 1,000 volume. The average volume for the last 3 months is 17,159 and the stock's 52-week low/high is $0.009999999/$0.020999999.

Cardiff Lexington Corporation (CDIX)

OTC Markets, TipRanks, Spotlight Growth, OTC Dynamics, Speculating Stocks, Stockhouse, Newsfilecorp, Seeking Alpha, MarketWatch, Dividend Investor, Investing.com, Market Exclusive, last10k, Financial Buzz, TradingView, Stockopedia, Morningstar, Junior Mining Network, Barchart, Nasdaq, Simply Wall St, GlobeNewswire, InvestorsHub, GuruFocus, and Stock Day Media reported beforehand on Cardiff Lexington Corporation (CDIX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cardiff Lexington Corporation is a diversified financial services holding company listed on the OTC Markets. It mainly focuses on the tax, debt, and real estate sectors. It is implementing a buy and build strategy taking advantage of proven management in private companies that become subsidiaries. The Company targets acquisitions of mature, high growth, niche companies.

Cardiff Lexington has its corporate headquarters in Fort Lauderdale, Florida. The Company previously went by the name Cardiff International, Inc. It changed its name to Cardiff Lexington Corporation in January of 2018. Cardiff Lexington Corporation was established in 2001.

The Company's strategy identifies and empowers select income-producing middle market private businesses and commercial real estate properties. Cardiff Lexington provides these companies the enhanced ability to raise money for operations or expansion, and an equity exit and liquidity strategy for the owner, heirs, and/or Investors. Cardiff also provides a proven experienced Cardiff Lexington management team to spearhead growth and expansion.

For investors, the Company provides a diversified lower risk to protect and safely enhance their investment through continually adding assets and holdings. A strong team of executives and advisors providing expert acquisition, market guidance, and added management value for subsidiaries and investors leads Cardiff Lexington.

Recently, Cardiff Lexington announced that it has divested its holdings in the food services sector. The Company has reached accord in principal with Mr. Frank Repicci and Mr. Gene Romeo respectively whereby Repicci's Italian Ice and Gelato and Romeo's New York Style Pizza will spin out as private companies no longer operating as subsidiaries of Cardiff Lexington.

The Cardiff Lexington Board of Directors has narrowed its forward emphasis to acquisitions in the financial services sector to build upon its tax subsidiaries with related debt, credit, billing, and real estate opportunities.

Mr. Alex Cunningham, Chief Executive Officer of Cardiff Lexington, stated, "Our "Buy and Build" strategy is targeting acquisition of middle market private niche financial service companies and real estate both mature, and, second stage with high growth potential. Repicci's and Romeo's no longer fit within our longer-term strategy and given their impact from COVID-19 for these companies to remain subsidiaries of a public entity exerts additional and unnecessary cost and pressure. This was a difficult decision to sell our food businesses but believe it to be in the best interest of our shareholders.""

Cardiff Lexington Corporation (CDIX), closed Tuesday's trading session at $0.081125, up 103.8317%, on 114,379 volume with 15 trades. The average volume for the last 3 months is 4,893 and the stock's 52-week low/high is $0.000097999/$0.869000017.

Cuentas, Inc. (CUEN)

GlobeNewswire, AI Stock Finder, PredictWallStreet, TeleTrader, Central Charts, Investing.com, GuruFocus, Stockhouse, last10k, Market Screener, Financial Buzz, Wallet Investor, PR Newswire, Simply Wall St, InvestorsHub, Corporate Information, and Accesswire reported previously on Cuentas, Inc. (CUEN), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Cuentas, Inc. is a top FinTech (Financial Technology) provider of mobile banking and payment solutions serving Latino and Hispanic consumers. The Company uses technical innovation together with existing and emerging technologies to deliver accessible, efficient, and reliable mobile, new-era and traditional financial services to consumers. The Company has its proprietary Cuentas General Purpose Reloadable (GPR) Card. Cuentas has its head office in Miami, Florida and the Company’s shares trade on the OTC Markets Group’s OTCQB.

Cuentas uses technology to bridge the gap between traditional financial services and the underbanked U.S. Latino population. The Company’s services include, but are not limited to, mobile banking, online banking, prepaid debit, bill pay, ACH and mobile deposits, cash remittance, peer to peer money transfer, and bank accounts to customers who previously could not obtain bank accounts.

The Cuentas General Purpose Reloadable (GPR) Card provides holders with digital wallets, discounts for purchases at major physical and online retailers, free telecom, and the ability to purchase digital content. The card will be available in more than 31,000 bodegas.

The Cuentas Fintech Card is an online bank account integrated with the Cuentas branded general purpose reloadable card (GPR). It provides a total online banking solution to all, including those without a U.S. government issued ID. Cuentas has begun a methodical and controlled rollout of the Cuentas Prepaid GPR card. It is at the same time improving the app through new features and capabilities, and also adding many more physical reloading locations.

Concerning Mobile Wallet, the in-app Mobile Wallet offers FinTech Card functionality for online and mobile purchases. The Cuentas Virtual Marketplace provides discounted gift cards to Cuentas cardholders. These can be stored in the Cuentas Mobile Wallet and be used online, sent electronically to friends or family, and redeemed for a physical gift card.

This past February, Cuentas announced the launch of the Cuentas Mobile App, enabling consumers for the first time to sign up for and use the Cuentas prepaid GPR (general purpose reloadable) Mastercard. The Cuentas App, available for download on the Apple App Store and on the Google Play Store for Android, permits consumers to easily activate their Cuentas prepaid Mastercard, review their account balance, and conduct financial transactions.

Cuentas, Inc. (CUEN), closed Tuesday's trading session at $2.39, up 44.8485%, on 20,846 volume with 32 trades. The average volume for the last 3 months is 1,919 and the stock's 52-week low/high is $1.58000004/$7.50.

Iconic Brands, Inc. (ICNB)

Stock News Union, Discovery Stocks, Insider Financial, Stockhouse, Barchart, InvestorsHub, Wallmine, 4-Traders, Wallet Investor, OTC Markets, GuruFocus, Marketwired, Street Insider, YCharts, Last10k, Trading View, Investors Hangout, Business Wire, Emerging Growth, Stockopedia, Stockwatch, and Simply Wall St reported earlier on Iconic Brands, Inc. (ICNB), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Iconic Brands, Inc. is a beverage company listed on the OTC Markets Group’s OTCQB. The Company’s expertise is developing, from inception to completion, alcoholic beverages for itself and third parties. It markets and places products into national distribution via long standing industry relationships. Iconic Brands offers wine and distilled alcoholic beverages, and also liquor based products infused with hemp and CBD. The Company is headquartered in Amityville, New York.

Iconic Brands is a leader in Celebrity and Private Label beverages. It obtains first-rate and innovative products from around the world and brands its products with globally recognized celebrities and corporate icons. The Company’s corporate mission is to be the industry leader in brand development, marketing, and sales of the highest quality alcoholic beverages.

Iconic Brands is under contract with United Spirits - a federally-licensed importer and distributor of alcoholic beverages. In addition, the Company is under contract with Mr. Dan Kay, who maintains a New York State warehousing license for alcoholic beverages.

Regarding Services, Iconic Brands’ takes a customer’s product idea from concept to completion. This includes everything from sourcing, flavor profiles, packaging, design, marketing and distribution. Iconic an also align a customer’s brand with select celebrity endorsement. Iconic markets its products under the Bivi, Bellissima, Bella, and Romano brand names.

Previously, Iconic Brands announced it entered into a Letter of Intent (LOI) to acquire recently formed Green Grow Farms, Inc. Green Grow Farms partners directly with farmers to transition their crops to hemp for the purpose of extracting Cannabidiol (CBD Isolate/Oil). It provides full support services and logistics to take product from seed to sale.

Iconic Brands also announced that Green Grow Farms secured a processor and material supplier agreement with one of the largest vertical Hemp processors in the world. The agreement is for an initial 2-year term. It allows for a minimum of 2 million pounds of biomass to be processed to CBD isolate, and sold under a revenue sharing agreement. With average CBD percentage and processing efficiency rates from Green Grow’s farming operations, two million pounds should process into roughly 40,000 kilograms of CBD Isolate.

More recently, Iconic Brands, in conjunction with its Licensed Partner, United Spirits, announced the introduction of Hooters Spirits, with the official debut at this year’s WSWA Conference. Hooters Spirits is a private label brand for Hooters of America, the iconic restaurant chain. The product portfolio comprises Hooters Vodka, Hooters Gin, Hooters Rum, Hooters Tequila, Hooters American Whiskey and Hooters Shooter, a cinnamon flavored whiskey.

Iconic Brands, Inc. (ICNB), closed Tuesday's trading session at $0.38, up 65.2174%, on 47,957 volume with 26 trades. The average volume for the last 3 months is 31,654 and the stock's 52-week low/high is $0.200000002/$1.00.

CIB Marine Bancshares, Inc. (CIBH)

OTC Markets, MarketWatch, 4-Traders, Morningstar, Marketwired, Investopedia, Zacks, TradingView, GuruFocus, Stock Traders Chat, Amigo Bulls, Investor Hangout, CapitalCube, Stockhouse, InvestorsHub, Wallet Investor, Money Hub, Wallmine, Penny Stock Hub, YCharts, and Silicon Investor reported earlier on CIB Marine Bancshares, Inc. (CIBH), and we report on the Company as well, here at the QualityStocks Daily Newsletter. 

Incorporated in 1985, CIB Marine Bancshares, Inc. operates as the bank holding company for CIBM Bank. The Bank provides banking and related services for small and middle-market business customers. CIB Marine Bancshares is headquartered in Waukesha, Wisconsin. In addition, the Bank has offices in Central and Northeastern Illinois, Milwaukee, and Indianapolis markets. CIB Marine Bancshares lists on the OTC Markets Group’s OTCQB. 

CIB Marine Bancshares operates via Banking and Mortgage Banking segments. It accepts demand, savings, and also time deposits. CIBM Bank operates as Marine Bank in its Indiana and Wisconsin markets, Central Illinois Bank in its central Illinois market, and Avenue Bank in its Chicagoland market. Located in Naperville, Illinois, the Avenue Mortgage division of the Bank serves all CIBM Bank markets.

CIBM Bank provides traditional banking services. These include a wide assortment of loan products. These include commercial loans, commercial real estate loans, commercial and residential construction loans, one-to-four family residential real estate loans, consumer loans, and commercial and standby letters of credit. Furthermore, services the Bank provides include acceptance of demand, savings and time deposits; commercial paper and repurchase agreements, and other banking services.

Recently, CIB Marine Bancshares announced its results of operations and financial condition for Q3 2018. Pre-Tax Net Income for the quarter was $1.2 million, the same as Q3 in 2017. For the nine months ending September 30, 2018, it was $3.3 million versus $3.1 million for the same period in 2017.

MR. J. Brian Chaffin, CIB Marine Bancshares’ President and Chief Executive Officer, said, “The third quarter results reflect improvements in all of our major business areas. We had a strong production quarter for our commercial loan portfolio with outstanding balances rising $19 million over the last 3 months, and our SBA and residential loan production are both up year to date and had solid third quarters.”

CIB Marine Bancshares, Inc. (CIBH), closed Tuesday's trading session at $17.00, up 13.33%, on 7,687 volume with 29 trades. The average volume for the last 3 months is 406 and the stock's 52-week low/high is $14.6499996/$17.00.

NRG Metals, Inc. (NRGMF)

Stockhouse, The Street, MarketWatch, Barchart, and 4-Traders reported earlier on NRG Metals, Inc. (NRGMF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

NRG Metals, Inc. searches for brine-based lithium targets in Argentina, Bolivia, and Chile. It has positioned itself for fast growth in the brines of South America. NRG Metals is operating in miner-friendly jurisdictions with first-class infrastructure, targeting battery-grade lithium and other forms of metal. NRG Metals is headquartered in Vancouver, British Columbia and the Company lists on the OTC Markets’ OTCQB.

NRG Metals’ aim is to quickly enter the lithium market through developing technically uncomplicated, limited environmental footprint projects in Argentina. The Hombre Muerto North Project in Argentina is in an area of lithium production and development. The Salar Escondido Project in Argentina is a drill ready, fully permitted, 29,000-hectare claim block. It represents an exploration opportunity to make a significant new lithium discovery.

NRG Metals’ focus is on identifying and establishing a project with the intent of producing an industrial grade lithium product. The Hombre Muerto North Project is a 3,297-hectare claim package comprising six concessions in Salta Province. Twenty surface samples collected in 2016-2017 range from 48 to 1,064 mg/L Li, averaging 587 mg/L Li, with seven samples more than 800 mg/Li. The property package comprises the Alba Sabrina, Tramo, Natalia Maria, Gaston Enrique, Viamonte, and Norma Edit concessions.

The Salar Escondido Project is in Catamarca Province, 40km south of Antofagasta de la Sierra. The Project area is strategically situated within the Lithium Triangle, in close proximity to one of the largest known lithium deposits in Argentina, and within the Puna Region. The region is an elevated plateau, which lies on the eastern side of the Andes Mountains. The area contains a number of highly mineralized salars. This includes the lithium producing salars – the aforementioned Hombre Muerto.

NRG Metals controls a dominant portion of the basin with 29,192 hectares under option. Surface sampling in fresh water zones returned anomalous Li values up to 50ppm and high carbonate values. Preliminary interpretation indicates four distinct zones.

Recently, NRG Metals reported additional assays from the second diamond drill hole at the Hombre Muerto North lithium project. The samples were taken from depths ranging from 91.0 to 230.5 m below surface. These assays range from 779 to 507 mg/L lithium with low Mg to Li ratios ranging from 2.3 to 3.0. The average for the entire hole is 638 mg/L Lithium with a Mg to Li ratio of 2.65 to 1.0.

Mr. Jose de Castro, Chief Operating Officer of NRG Metals, said, "We are extremely enthusiastic about the diamond drilling results, as well as the results from the pumping well. These results demonstrate the presence of high-grade lithium bearing brine across the breadth of our Tramo property. We look forward to completing the second pumping well and to fast tracking the project to production."

NRG Metals, Inc. (NRGMF), closed Tuesday's trading session at $0.30, up 42.8571%, on 130,683 volume with 47 trades. The average volume for the last 3 months is 8,607 and the stock's 52-week low/high is $0.039999999/$0.367300003.

Inspyr Therapeutics, Inc. (NSPX)

BUYINS.NET and Zacks reported earlier on Inspyr Therapeutics, Inc. (NSPX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Inspyr Therapeutics, Inc. is a clinical-stage biotechnology company based in Westlake Village, California. It is developing novel prodrug therapeutics for the treatment of cancer. Mipsagargin is its lead agent. Mipsagargin is in human clinical trials for patients’ with numerous different tumor types. Inspyr Therapeutics’ team has considerable pharmaceutical industry and scientific experience.

The Company lists on the OTC Markets Group’s OTCQB. It previously went by the name GenSpera, Inc. It changed its name to Inspyr Therapeutics, Inc. in August of 2016.  

Mipsagargin (G-202) is a prodrug in human clinical trials for patients with hepatocellular carcinoma (HCC, or liver cancer), glioblastoma (GBM, or brain cancer) and prostate cancer. Mipsagargin has been studied in a Phase 2 clinical trial in patients with hepatocellular carcinoma (liver cancer). It has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication.  

Mipsagargin is now undergoing evaluation in an open-label, single-arm, Phase II clinical study in patients with glioblastoma (brain cancer). In addition, it is undergoing evaluation in two Phase II clinical pilot studies in patients with prostate and clear cell renal cancer.  

Inspyr Therapeutics has started the second development program for Mipsagargin as part of a combination therapeutic approach. This new program centers on the treatment of gastric cancer.

Inspyr has started a preclinical study in gastric cancer PDX tumor models that express varying levels of PSMA, the target of Mipsagargin. In this initial study, Mipsagargin will undergo evaluation initially in combination with paclitaxel.   

Inspyr Therapeutics is developing a novel technology platform. This platform combines a strong therapeutic (thapsigargin) with a patented prodrug delivery system that targets the release of drugs within solid tumors without the side effects of chemotherapeutic agents. This unique platform technology has the potential to work across a range of drugs that precisely target different cancers.       

Inspyr Therapeutics previously announced the start of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator (ARM) based compounds. The preclinical study is led by Elizabeth Kang, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This study will assess these compounds for the prevention of graft versus host disease (GvHD), a potential side effect of allogeneic stem cell transplants.

Inspyr Therapeutics, Inc. (NSPX), closed Tuesday's trading session at $0.048, up 37.1429%, on 138,771,414 volume with 5,892 trades. The average volume for the last 3 months is 10,184,311 and the stock's 52-week low/high is $0.0005/$1.13399994.

eWellness Healthcare Corp. (EWLL)

Penny Stock Prodigy and StockHideout reported earlier on eWellness Healthcare Corp. (EWLL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Culver City, California-based eWellness Healthcare Corp. develops a telemedicine platform. This platform is for providing Distance Monitored Physical Therapy programs. These programs are for pre-diabetic, cardiac, and health challenged patients via contracted physician practices and healthcare systems. The Company has launched PHZIO. The design of this telemedicine platform is to extend and scale a physician’s practice. eWellness Healthcare is the first physical therapy telemedicine enterprise to provide insurance reimbursable real-time distance monitored treatments. eWellness Healthcare lists on the OTC Markets Group’s OTCQB.

The Company’s business model is to license its PHZIO platform to any physical therapy (PT) clinic in the United States and/or have large-scale employers use its PHZIO platform as a completely PT monitored corporate wellness program. eWellness Healthcare’s PHZIO is a Physical Therapy Telemedicine platform. It extends a traditional practice online.

The chief features of the PHZIO platform include video treatment protocols, real-time patient monitoring, patient induction forms, a patient video journal, and post treatment evaluations. In addition, main features include integrated billing, patient metrics, and user administration & customization.

Moreover, PHZIO scales a practice’s billable rates. It also provides tools to make growing a business easier. Pertaining to the Patient Dashboard, the PHZIO Dashboard enables clients to login securely to access prescribed treatment protocols. PHZIO is user-friendly and highly reliable to operate for PT and Patient. Furthermore, it’s a total on-line PT telemedicine intervention system.

eWellness Healthcare has launched a PHZIO PT clinic on-boarding website. The site includes a telehealth profitability calculator to illustrate to prospective PT clinics the additional profits they can make through using the PHZIO platform.

eWellness Healthcare anticipates adding Artificial Intelligence (AI) tools and predictive analytics into its PHZIO platform by the end of this year. The anticipation is that the new AI and predictive analytics will combine the Company’s existing remote monitoring capabilities with machine learning and intelligent analytics, which take advantage of patient health data to improve healthcare outcomes.

Evolution Physical Therapy has added eWellness Healthcare's Telehealth PT Services at its four clinical locations in Los Angeles, California. This includes Culver City, Playa Vista, Beverly Hills, and Brentwood. Mr. Darwin Fogt, Chief Executive Officer of eWellness Healthcare, owns Evolution Physical Therapy.

Recently, eWellness Healthcare and Total Release Physical Therapy announced an Integration & Marketing Agreement. Total Motion Release Seminars (TMR) is a proprietary physical therapy methodology developed by Mr. Tom Dalonzo-Baker, MPT. TMR is a full-body oriented assessment and treatment approach. TMR helps patients lessen their pain and impairments which limit their function. The treatment approach is created to allow physical therapists to interact and treat their patients remotely. The expectation is that integration with PHZIO will be extensively adopted within the TMR community.

eWellness Healthcare Corp. (EWLL), closed Tuesday's trading session at $0.0002, up 100.00%, on 270,681,576 volume with 194 trades. The average volume for the last 3 months is 325,095,817 and the stock's 52-week low/high is $0.000000999/$75.00.

The QualityStocks Company Corner

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and health-care platform, today announced that its Bonum Health subsidiary has partnered with SingleCare, the prescription savings service. According to the update, the collaboration is designed to enhance Bonum’s enterprise telehealth solutions with prescription discounts powered by SingleCare. The enterprise service will be offered to national, regional and local pharmacies to promote the benefit to underserved communities and uninsured patients. To view the full press release, visit http://nnw.fm/y0Mt6

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

 

Trxade Group Inc. (NASDAQ: MEDS), closed Tuesday's trading session at $6.54, up 7.9208%, on 177,827 volume with 1,200 trades. The average volume for the last 3 months is 54,303 and the stock's 52-week low/high is $4.01000022/$11.6000003.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology solutions provider, together with BIGtoken(R) Inc., a company started as a division of SRAX, today announced that George Stella will be appointed chief revenue officer (“CRO”) of BIGtoken following its transition into a standalone publicly traded company. Stella, executive vice president at SRAX, brings more than 20 years of digital media experience. To view the full press release, visit http://nnw.fm/vmQSi

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Tuesday's trading session at $2.56, up 1.5873%, on 134,587 volume with 356 trades. The average volume for the last 3 months is 134,110 and the stock's 52-week low/high is $1.04999995/$3.35739994.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Houston, Texas-based biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) continues to achieve milestones in its drive to defeat glioblastoma multiforme (“GBM”), a relentless type of brain tumor known for very rapid progression and very short survival periods in nearly all patients once they’ve been diagnosed.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $1.9399, up 4.8595%, on 26,807 volume with 92 trades. The average volume for the last 3 months is 100,689 and the stock's 52-week low/high is $1.25820004/$5.68989992.

Recent News

The Movie Studio Inc. (OTC: MVES)

The QualityStocks Daily Newsletter would like to spotlight The Movie Studio Inc. (OTC: MVES).

The Movie Studios (OTC: MVES), a vertically integrated motion-picture production and distribution company, is looking to be a major player in the growing streaming market. A recent CompariTech article highlighted opportunity for content providers like MVES, reporting that a growing number of viewers around the world were looking to online streaming as a preferred option for viewing shows, movies, sports and more (https://nnw.fm/QlA6k). To view the full article, visit: https://nnw.fm/pESN6

The Movie Studio Inc. (OTC: MVES) is a vertically integrated motion picture production company focused on acquiring, developing, producing and distributing independent motion picture content for worldwide consumption via subscription and advertiser video on demand (SVOD/AVOD), over the top (OTT) platforms, foreign sales and various media devices. The company is currently engaged in establishing its own OTT VOD platform to integrate both its own and aggregated feature film projects, television programming and other media intellectual properties. The Movie Studio is disrupting traditional media content delivery systems with its digital business model of motion picture distribution, and the company intends to create a direct server access platform of its content with geo-fractured territories for worldwide distribution.

The company has launched The Movie Studio App on Google Play and the App Store, enabling users to both view the company’s content and potentially become part of it. The app is in the completion stage, and The Movie Studio is conducting its final beta test of the app’s unique “audition submission” function, leveraging the company’s “Watch Our Movies, Be in Our Movies!” content platform and “Everyone’s a Star” campaign, which will be marketed via social media. Using the app, subscribers can upload a thumbnail photo of themselves along with a selfie video audition submission that showcases them reading character dialog. Audition submissions will then be reviewed by producers for possible participation of the auditionee in upcoming feature films.

The audition submission function provides the subscriber the ability to disrupt traditional motion picture casting and management, enabling access to participation in The Movie Studio’s independent motion picture and media content. At the same time, for the company this significantly reduces capital expenditures associated with those traditional media mechanisms. The Movie Studio’s unique business model capitalizes on the global demand for film content through the production and distribution of its own films while also providing opportunities for direct viewer involvement in its content.

The company operates using a growth-by-acquisition strategy that includes:

  • Purchasing legacy film libraries.
  • Upgrading acquired films to 4K resolution and remonetizing with “new” film content on popular VOD streaming platforms across the internet.
  • Strategic partnerships and media content alignment with other OTT platforms and cross-collateralization of leverageable media assets for worldwide distribution.
  • Producing micro-budget motion picture content with substantial production value utilizing new 4K technology and the company’s extensive legacy resources and unique production process, thereby significantly reducing capital expenditures while allowing for the potential of significant return on investment (ROI) with one successful production.
  • Controlling its revenue streams through server-driven geo-fracturing global territories and its own OTT platform.

Currently, The Movie Studio is producing three upcoming feature films: “Cause and Effect,” “The Last Warhead” and “PEGASUS” — all with completed electronic press kits and pitch decks and fully produced motion picture-quality trailers ready for talent, distribution and financial integration.

The company has been successful in producing, casting and distributing its films on major SVOD platforms without recognizable stars, which reduces capital expenditures. However, The Movie Studio intends to integrate recognizable stars into the productions at value propositions either pre- or post-completion of the intellectual property.

Through successful beta testing, The Movie Studio has monetized film assets on the Amazon, tubi tv, Comcast and Showtime platforms.

The company’s proposed server-based model will provide licensing payment from global territories without third-party distribution fees, which have traditionally been as high as 35%.

Founded in 1961 and formerly known as Destination Television, Inc., the company changed its name to The Movie Studio, Inc. in November 2012. The Movie Studio is headquartered in Fort Lauderdale, Florida.

Cord-Cutting Creates Opportunity for VOD Players

Consumers are no longer content waiting for their favorite programming to come on the air – they expect instant streaming access where and how they want it. This has led to increased “cord cutting,” with consumers severing ties with their traditional pay TV providers in favor of digital streaming services.

With the advent of smart TVs with app integration, consumers can now watch what they want to watch when they want to watch it, fracturing traditional cable bundling mechanisms.

With pay TV usage steadily declining – satellite and cable TV businesses in the United States lost approximately 6 million customers in 2019 alone – streaming platforms are poised to potentially replace traditional pay TV distribution models altogether. Approximately 12,000 U.S. consumers are cutting the cord every day.

As this shift in media delivery continues and as digital devices become more sophisticated and bandwidth increases, VOD platforms have the potential to scale significantly. The Hollywood “streaming wars” of recent years have created an environment in which smaller competitors, like The Movie Studio, are able to emerge as major brands.

The Movie Studio Inc. (OTC: MVES), closed Tuesday's trading session at $0.009, up 5.8824%, on 93,198 volume with 9 trades. The average volume for the last 3 months is 215,883 and the stock's 52-week low/high is $0.006099999/$0.039999999.

Recent News

Sustainable Green Team Ltd. (SGTM)

The QualityStocks Daily Newsletter would like to spotlight Sustainable Green Team Ltd. (SGTM).

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally-beneficial solutions for tree and storm waste disposal, recently announced that Central Florida Arborcare, its wholly-owned subsidiary, was awarded a one-year contract to supply tree trimming and related services to the county, renewable for an additional four times over a one-year period. Along with tree services, SGTM provides debris hauling and waste removal as part of its overall operations that transform organic waste into environmentally-friendly products such as mulch and playground surfacing material.

Sustainable Green Team Ltd. (OTC: SGTM), through its subsidiaries, including National Storm Recovery LLC (DBA Central Florida Arbor Care and Mulch Manufacturing Inc.), provides tree services, debris hauling, removal and bio-mass recycling, manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.

Environmentally Friendly

SGTM and the solutions provided by its Sustainable Green Team are founded in sustainability. The company’s vertically integrated operations begin with the collection of tree debris through its tree services division and collection sites. Tree bio-mass is then moved through the processing division for recycling and manufacturing into a variety of organic, attractive, next-generation mulch products to be packaged and sold to retailers, landscapers, installers and garden centers.

The company’s solutions create a synergistic and environmentally beneficial solution to tree and storm waste disposal that historically has created an environmental burden on landfills and disposal sites around the nation.

SGTM’s customers include governmental, residential and commercial customers and now big box retailers. The company is headquartered in Florida.

Strategic Acquisition

SGTM in February 2020 acquired 35-year-old industry leader and innovator Mulch Manufacturing Inc., an Ohio corporation. Structured as a share exchange, this strategic partnership provides SGTM with a significantly larger footprint in the mulch industry.

The acquisition includes Mulch Manufacturing’s national and international distribution agreements, an increase in production and packaging capacity, and its sales contracts with numerous big box retailers. Mulch Manufacturing includes mulch production, sawmill operation, Natures Reflections colorant manufacturing and equipment manufacturing.

Next-Gen Products

SGTM’s vision and commitment to the environment is paired with Mulch Manufacturing’s revolutionary “next-generation” mulch product, Nature’s Reflection’s Softscape®.

Softscape mulch products, created from natural forest products, are color-enhanced with environmentally safe colorants to provide four-year color retention and are free from contaminants. Safe for people and pets, Softscape allows water and air to penetrate soil and roots, which is vital to plant health and growth.

Expansion Plans

SGTM plans to expand its operations through a combination of organic growth, through its partnership with a nationally recognized waste disposal company, and through strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified.

The company has received final zoning approval for its 100-acre site, located in Lake County, Astatula, Florida, which will serve as its flagship tree debris collection site. The facility will also house the company’s mulch manufacturing, soil composting and production bagging. This prime location includes a 5,000-square-foot building that contains warehouse and office space. The 100-acre property can accommodate millions of cubic yards of organic debris and will allow SGTM’s debris hauling division to realize significant savings on its transportation costs.

SGTM has chosen as its new headquarters the 100,000-square-foot Mulch Manufacturing building in Jacksonville, Florida. The facility comprises centralized operations of Mulch Manufacturing Inc. and National Storm Recovery LLC and has ample room to expand as needed.

Leadership

SGTM’s leadership team boasts more than 40 years of next-level experience with mulch manufacturing, treating and caring for trees. This team is guided by a roster of highly qualified professionals:

  • Tony Raynor, Chief Executive Officer
  • Edward Lee, Chief Operating Officer
  • Ralph Spencer, Director of Business Development, Strategic Acquisitions
  • Steve Ogden, ISA-Certified Arborist
  • Rick Starcher, Master Chemist
  • Peder K. Davisson, Esq., Corporate/Securities Counsel

Sustainable Green Team Ltd. (OTC: SGTM), closed Tuesday's trading session at $1.35, even for the day, on 767 volume with 6 trades. The stock's 52-week low/high is $0.05/$2.4999001.

Recent News

DarioHealth Corp. (NASDAQ: DRIO)

The QualityStocks Daily Newsletter would like to spotlight DarioHealth Corp. (DRIO).

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, today announced that Vitality Group has chosen the company's digital therapeutics solutions for inclusion in Vitality's new Gateway Flex offering. According to the update, Gateway Flex enables employers to personalize the health-care experience to meet the diverse and rapidly changing needs of their employees and allows employers to pay only for solutions in which their employees engage. To view the full press release, visit: https://ibn.fm/PySeF. Also today, the company was featured in a publication from BioMedWire, examining how, according to the work of Rutgers researchers published in the journal Epigenetics, kids who are born to diabetic mothers are prone to aging faster biologically and they may also be more susceptible to high blood pressure and obesity later in life.

New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

  • AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
  • Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (RPM) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

DarioHealth Corp. (DRIO), closed Tuesday's trading session at $12.9, off by 1.6768%, on 202,301 volume with 1,345 trades. The average volume for the last 3 months is 268,792 and the stock's 52-week low/high is $3.01999998/$22.4899005.

Recent News

Processa Pharmaceuticals Inc. (NASDAQ: PCSA)

The QualityStocks Daily Newsletter would like to spotlight Processa Pharmaceuticals Inc. (NASDAQ: PCSA).

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical needs, has appointed a new chief operating officer. Michael Floyd, a serial entrepreneur who has formed several life science organizations and served as a senior executive in those organizations, will be taking over that role. To view the full press release, visit http://ibn.fm/UwLvl. Also today, the company was featured in a publication from BioMedWire.

Processa Pharmaceuticals Inc. (NASDAQ: PCSA) aims to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions. In support of this goal, the company has assembled an unparalleled management team, board of directors and product development team featuring experts in developing drug products, from IND-enabling studies to NDA submission. In total, the team’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and Drug Administration (FDA) and more than 100 meetings with the FDA while working on more than 50 drug development programs, including drug products targeted to orphan disease and unmet medical need conditions.

Headquartered in Hanover, Maryland, Processa has built a pipeline of drugs which already have some proof-of-concept clinical data supporting clinical use in their selected indications.

Development Pipeline

The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete. More specifically, Processa:

  1. Acquires drugs that already have some clinical data to support the targeted treatment – whether it be the drug itself, an analog of the drug or a drug with similar pharmacological targets;
  2. Navigates through the FDA, collaborating with the reviewers to define a complete development program; and
  3. Develops each drug over the course of 2-5 years, out-licensing the drug either just prior to pivotal study after Phase 2b or after the completion of the pivotal study.

Processa’s current development pipeline features multiple drug candidates, including PCS499 and PCS100. The company has also announced three additional licensing agreements since June 2020, further bolstering its clinical efforts. Each drug is briefly described below.

PCS6422

On August 27, 2020, Processa announced its entry into a contingent precedent exclusive licensing agreement with Elion Oncology Inc. to develop, manufacture and commercialize eniluracil (PCS6422) globally. PCS6422 is an oral drug to be administered with fluoropyrimidine cancer drugs (e.g., capecitabine, 5-FU) to decrease the breakdown of the cancer drug to inactive metabolites or metabolites that are known to cause unwanted side effects and to increase the anti-cancer related metabolites.

An IND for a Phase 1B study was cleared by the FDA in May 2020. The study will evaluate the safety and tolerability of several dose combinations of PCS6422 and capecitabine in advanced GI tumor patients. Processa intends to enroll the first patient in 1H2021, obtain interim results, and have a final report completed in 2H2022.

“Having worked on 5-FU and other cancer agents in the past, adding PCS6422 to our pipeline and expanding our involvement in oncology was an easy decision given the significant impact that PCS6422 may have on improving the efficacy and safety of capecitabine or other fluoropyrimidines,” CEO Dr. David Young said of the agreement.

PCS499

PCS499 as a potential treatment for necrobiosis lipoidica (“NL”) was first presented to the FDA in a pre-IND meeting in 2018. In 2019, it was the subject of an IND submission and a promising Phase 2 safety study. On March 30, 2020, Processa announced a successful meeting with the FDA regarding the design and execution of the next clinical study to evaluate the ability of PCS499 to completely close ulcers in patients with NL.

“We are pleased with the outcome of the FDA meeting and the feedback we received from the FDA. We believe that the results from our completed Phase 2 trial in NL patients, especially those with more severe ulcerated forms of NL, are encouraging and we appreciate the guidance provided by the FDA regarding our next clinical trial and the requirements to support our NDA submission,” Dr. David Young, CEO of Processa, stated in the news release.

NL is a chronic, disfiguring condition affecting the skin and tissue under the skin, typically on the lower extremities, with no currently FDA-approved treatments. More severe complications can occur, such as deep tissue infections and osteonecrosis, threatening the life of the limb. Approximately 22,500 – 55,500 people in the United States and more than 150,000 – 400,000 people worldwide are affected by the ulcerated form of NL.

YH12852

On August 20, 2020, Processa announced its entry into an agreement with Yuhan Corporation, a South Korean firm, to license YH12852, a small molecule drug in development for the treatment of functional gastrointestinal (GI) disorders. Under the terms of the agreement, Processa will acquire the rights to a portfolio of patents with an exclusive license to develop, manufacture and commercialize YH12852 globally, excluding South Korea.

YH12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Other 5-HT receptor agonists with less 5-HT4 selectivity have been shown to successfully treat GI mobility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia and gastroparesis. The less selective 5-HT4 agonists, such as cisapride, have been removed from the market because of the cardiovascular side effects associated with the drugs binding to other receptors, especially 5-HT receptors other than 5-HT4.

CEO Dr. David Young called the agreement “further evidence of Processa’s commitment to seek out novel treatments for unmet medical conditions.” Processa intends to meet with the FDA in early 2021 to further define the clinical development program. In 2021, Processa expects to initiate a Phase 2 trial in a functional GI motility-related disorder that that needs better therapeutic options, such as postoperative ileus and opioid-induced constipation.

ATT-11T

On June 1, 2020, Processa announced its entry into a licensing agreement with Aposense Ltd. for the patent rights and know-how to develop and commercialize ATT-11T, a next generation irinotecan cancer drug. In the release, CEO Dr. David Young noted that the licensing deal fit with Processa’s strategy to “continue to bring innovative products to patients with an unmet medical need condition.”

ATT-11T is a novel lipophilic anti-cancer pro-drug that is being developed for the treatment of the same solid tumors as prescribed for irinotecan. This pro-drug is a conjugate of a specific proprietary Aposense molecule connected to SN-38, the active metabolite of irinotecan. The proprietary Aposense molecule on ATT-11T allows ATT-11T to bind to cell membranes to form an inactive pro-drug depot on the cell, with SN-38 preferentially accumulating in the membrane of tumors cells and the tumor core. This unique characteristic is expected to make the therapeutic window of ATT-11T wider than irinotecan, such that the anti-tumor effect of ATT-11T will occur at a much lower dose than irinotecan with a milder adverse effect profile than irinotecan. The wider therapeutic window will likely lead to more patients responding with less side effects when on ATT-11T compared to irinotecan.

The ATT-11T licensing agreement is conditioned upon Processa’s closing of a satisfactory financing round and the listing of the company’s shares on the Nasdaq or NYSE, among other conditions.

PCS100

On September 3, 2020, Processa announced its entry into an exclusive worldwide license agreement with Akashi Therapeutics to develop and commercialization Akashi’s lead drug, HT-100. Rebranded PCS100, the candidate is an anti-fibrotic, anti-inflammatory drug demonstrated to have some clinical anti-fibrotic effect in children. Processa intends to develop PCS100 first in rare adult fibrotic related diseases such as focal segmental glomerulosclerosis (FSGS), idiopathic pulmonary fibrosis (IPF) or Scleroderma, where there are still few therapeutic options.

Management Team

David Young, Pharm.D., Ph.D. is the CEO and founder of Processa. He has over 30 years of pharmaceutical research, drug development and corporate experience. Young has served in leadership roles with a number of pharmaceutical firms throughout his career, including serving as founder and CEO of Promet Therapeutics LLC since 2015 and as Chief Scientific Officer of Questcor Pharmaceuticals from 2009 to 2014. At Questcor, he was responsible for working with the FDA on modernizing the Acthar Gel label and for obtaining FDA approval in infantile spasms. In total, Young has met with the FDA more than 100 times on more than 50 drug products and has been a key team member on more than 30 NDA/supplemental NDA approvals.

Sian Bigora, Pharm.D., is Processa’s Chief Development Officer and founder. She has over 20 years of pharmaceutical research, regulatory strategy and drug development experience, working closely with Young. Prior to joining Processa, Bigora served as Co-Founder, Director and Chief Development Officer at Promet Therapeutics LLC and as Vice President of Regulatory Affairs at Questcor Pharmaceuticals from 2009 to 2015, where she led efforts to modernize the Acthar Gel label and obtain FDA approval in infantile spasms – events which were of material importance to Questcor’s subsequent success.

Patrick Lin is Chief Business & Strategy Officer and founder of Processa. He has over 20 years of financing and investing experience in the biopharma sector. Prior to joining Processa, Lin served as Co-Founder and Chairman of Promet Therapeutics LLC. He is also founder and managing partner of Primarius Capital, a family office that manages public and private investments focused on small capitalization companies.

James Stanker has served as CFO of Processa since 2018. He has over 30 years of financial and executive leadership experience in the areas of accounting principles and audit standards, regulatory reporting, and fiscal management and strategy. He served in a financial leadership role as an audit partner at Grant Thornton from February 2000 until his retirement in August 2016, where he was responsible for managing audit quality in the Atlantic Coast market territory.

Wendy Guy is the Chief Administrative Officer and founder of Processa. She has more than two decades of experience in business operations, having worked closely with Young over the last 18 years in corporate management and operations, HR and finance. Prior to joining Processa, she was Co-Founder, Director and Chief Administrative Officer of Promet Therapeutics LLC and Senior Manager, Business Operation over the Maryland office for Questcor Pharmaceuticals.

Processa Pharmaceuticals Inc. (NASDAQ: PCSA), closed Tuesday's trading session at $4.63, off by 4.5361%, on 139,960 volume with 466 trades. The average volume for the last 3 months is 18,758 and the stock's 52-week low/high is $3.40000009/$18.00.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) was featured today in a publication from MiningNewsWire, examining how the World Economic Forum estimates that robotics and automation can avert about 10,000 injuries within the metals and mining industries in just a decade, and that autonomous hauling could improve productivity by at least 15-30%. These figures are realistic and they highlight why autonomous mining should be pursued with urgency. Here are some of the things that need to happen for autonomous mining to become a widespread reality.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Tuesday's trading session at $1.65, off by 1.7857%, on 807,388 volume with 1,793 trades. The average volume for the last 3 months is 1,578,083 and the stock's 52-week low/high is $0.779999971/$2.3499999.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Carl Schwartz, the CEO of Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has recently published a letter to the company’s shareholders elaborating on the company’s latest achievements as well as their prospects going forward (https://ibn.fm/L1mA8).

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Tuesday's trading session at $0.7732, off by 3.591%, on 350,288 volume with 701 trades. The average volume for the last 3 months is 1,416,315 and the stock's 52-week low/high is $0.730499982/$5.38999986.

Recent News

Kaival Brands Innovations Group Inc. (KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (KAVL).

Kaival Brands (OTCQB: KAVL), a company focused on developing products into mature, dominant brands, achieved a 44% increase in revenues for the third quarter 2020 and is in the process of establishing national distribution channels for future growth. To view the full article, visit: https://nnw.fm/BdghA. Also today, NetworkNewsWire released a report on the company detailing the Centers for Disease Control and Prevention report today that smoking is the leading cause of preventable death in the world (https://nnw.fm/SajJo). With the help of new and innovative cessation products, the  7 million deaths that occur every year due to smoking could be prevented — and Kaival Brands Innovations Group (OTCQB: KAVL) is determined to do all it can to make it happen.

Kaival Brands Innovations Group Inc. (KAVL) is focused on growing and incubating innovative and profitable products into mature, dominant brands. It aims to develop internally, acquire or exclusively distribute these products, helping them grow into market-share leaders by providing superior quality that is recognizable in their individual industries.

Formerly known as Quick Start Holdings Inc., the company changed its name to Kaival Brands Innovations Group Inc. (also known as Kaival Brands) in July 2019. Headquartered in Grant, Florida, the company commenced business operations on March 9, 2020.

Bidi™ Stick – Revolutionizing the Vaping Experience

On March 9, 2020, Kaival Brands entered into a partnership with Bidi Vapor LLC. The latter granted Kaival Brands exclusive global distribution rights for the innovative Bidi™ Stick.

Bidi™ Stick is a completely self-contained disposable product that is tamper-proof and recyclable. The innovative product is made from high-quality components and equipped with a long-lasting battery and class A nicotine. Its product engineering also includes a sensitivity control system, along with a proven mechanism designed to help identify and eliminate counterfeit products.

Available in 11 flavors, the Bidi™ Stick offers a premium vaping experience for adult consumers only. From its packaging design to its marketing strategies, Bidi Vapor makes sure that everything is compliant with government regulations.

On March 31, 2020, Kaival Brands partnered with QuikfillRx Digital as a digital service provider to help promote and commercialize the Bidi™ Stick. As a direct result of the partnership, Kaival Brands received back-to-back orders for the vaping device, totaling approximately $135,000, from sizable national convenience chains.

On September 8, 2020, the company announced that Bidi Vapor had submitted its Premarket Tobacco Product application (PMTA) to the U.S. Food and Drug Administration (FDA) for review. In total, over 285,000 pages of research, studies and surveys were submitted to support the application of Bidi™ Stick’s 11 variants.

“We are confident that, upon review, the FDA will authorize Bidi Vapor’s Bidi™ Stick for continued marketing in the United States,” Niraj Patel, President and CEO of Kaival Brands, stated in a news release (http://nnw.fm/unAyG).

Bidi Vapor is an industry leader in recycling – a position that was furthered through the creation of the Bidi Cares Initiative. The program encourages users to recycle their used Bidi™ Sticks instead of trashing them. As motivation, Bidi Vapor offers a free Bidi™ Stick for every 10 used devices recycled by a consumer. Kaival Brands is the exclusive recycling provider for the initiative.

Partnership Impact and Market Outlook

Bidi Vapor is a related party to Kaival Brands, as it is owned by Kaival Brands CEO Nirajkumar Patel. Patel is also the majority stockholder of Kaival Brands, placing both entities under common control.

The partnership has already had a positive impact on Kaival Brands, helping the company expedite growth, as evidenced by its Q2 financial results. According to Kaival Brands’ consolidated fiscal results for the quarter that ended on April 30, 2020, its revenues grew to approximately $22.5 million from no revenue in the same quarter of 2019. The company also scored a gross profit of $4.2 million for the three-month period. Net income was reported at $2.8 million for the quarter, compared to a net loss of about $4,000 in the second quarter of 2019. The company ended the second quarter of 2020 with a cash balance of $2 million (http://nnw.fm/44sq4).

The positive results are primarily an effect of Bidi™ Stick distribution amid the growing worldwide demand for high-quality vape products, as Patel explained in a news release. “Our focus now is to continue to increase revenues by increasing Bidi Vapor’s market share in the vaping industry,” he added.

Internationally, Kaival Brands has already taken steps to expand distribution of the Bidi™ Stick into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.

To this end, the company has set up a market engagement and sales force to reach a higher volume of retail and wholesale customers. It also created a dedicated customer support team to provide high-quality service and an enhanced customer experience.

Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium experience. The company wants to set higher standards to transform perceptions and elevate consumer experience in the vape and CBD industries, with a goal of increasing market share in the ever-growing vaping industry. In 2019, the reported global market for the vaping industry alone was $12.4 billion. These forecasts indicate a potential CAGR of 23.8% through 2027.

Cancellation of 300 Million Shares of Common Stock

In August 2020, the company canceled 300 million shares of common stock, marking a 52.1 percent reduction in its issued and outstanding shares of common stock (http://nnw.fm/W7s9T). Currently, the company’s outstanding common shares total 277,282,630. The cancelation was done in exchange for three million shares of Series A Preferred Stock. The Series A Preferred Stock cannot be converted before November 2023, barring any event that may trigger early conversion.

According to Patel, this move will benefit all shareholders and help maintain stability of the market pricing of remaining common stock. The overall goal is to increase value for long-term investors.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Prune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Kaival Brands Innovations Group Inc. (KAVL), closed Tuesday's trading session at $0.535, off by 1.2915%, on 35,844 volume with 23 trades. The average volume for the last 3 months is 178,825 and the stock's 52-week low/high is $0.006/$1.09000003.

Recent News

Pac Roots Cannabis Corp. (CSE: PACR)

The QualityStocks Daily Newsletter would like to spotlight Pac Roots Cannabis Corp. (PACR).

Pac Roots Cannabis Corp. (CSE: PACR) was featured today in the 420 with CNW by CannabisNewsWire. For the past couple of years, attitudes towards cannabis have been on the mend. Although the controversial plant is still considered illegal at the federal level, over 30 states  have legalized it to varying degrees. Renowned for a long time due to its psychoactive abilities, cannabis is increasingly being considered medicinal, with plenty of people using it to help manage conditions like chronic pain in lieu of pharmaceuticals.

Pac Roots Cannabis Corp. (CSE: PACR) is a Canadian cannabis company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach.

The company began operations in 2012, with activities primarily directed toward exploration and development of mineral properties in Canada. Today, it is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top quality products. Pac Roots has announced multiple promising initiatives in recent months, including its formation of an outdoor premium hemp joint venture with partner Rock Creek Farms in British Columbia, Canada, and its agreement to acquire all issued and outstanding shares of a firm holding 250 acres of land in the famed Fraser Valley Region of British Columbia.

Pac Roots is also in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through an elite line of 350+ unique, high-grade cultivars. Pac Roots expects to receive a cultivation license for the facility in the fourth quarter of 2020.

High-End Selectively Bred Genetics

Pac Roots focuses on high-end genetics in order to maximize the quality of its products while maintaining high yields and profit margins.

Through the process of artificial selection, farmers and cultivators have been adapting their plants to develop particular phenotypic traits for generations. Historically, this practice was restricted to underground cannabis producers developing their own strains.

The legalization of the cannabis industry has given producers access to thousands of cultivars located throughout the world while accelerating research into cannabis genetics. By carefully selecting strains, growers can control the size, color, smell, density and texture of cannabis buds, thereby creating distinctive, premium cannabis products.

Plants are bred to thrive in specific growing environments. This maximizes the yield of high-quality, resilient cannabis. Medical cannabis strains can also be tailored for specific medicinal purposes.

A strategic partnership with Phenome One, a plant breeding management and analytics firm, gives Pac Roots access to some of the world’s best cannabis genetics from the largest genetic library in Canada. The company is using these genetics to develop unique strains featuring a variety of beneficial characteristics.

The company’s 350+ licensed live cultivars and over 1,800 seed varieties are the result of a meticulous gene selection process, through which as many as 600 individual plants may be grown to produce a single strain. Selecting optimized genetics in this way provides benefits beyond simply producing a high-end product. In addition to potency and bud quality, cannabis plants are bred for yield and resilience. By selecting genetics that result in larger and more numerous buds on each plant, Pac Roots is able to grow more cannabis per grow light.

Breeding plants to be more resilient also reduces the cost and labor required. These factors, combined with the premium price point associated with top-quality cannabis, have the potential to improve Pac Roots’ overall profit margin.

Partnership with Phenome One

Pac Roots has secured its cultivars through a strategic licensing agreement with Phenome One. Under the agreement, Pac Roots has unlimited access to Phenome One’s live genetic library, including any of Phenome One’s cultivars and its growing, breeding and cloning IP.

Phenome One is an agricultural technology company focused on providing software solutions to seed companies. Phenome One’s platform gives its partners access to a massive database of detailed information on over 350 unique cannabis cultivars to support each stage of the breeding process. Each cultivar has been laboratory analyzed and rigorously field-tested, with data going back more than 30 years.

Using Phenome One’s data, Pac Roots plans to grow a variety of cannabis plants optimized for certain traits. One such trait will be plants with an abundance of cannaflavin, a rare terpene with high anti-inflammatory properties. Phenome One’s library could enable Pac Roots to produce plants that are bred to thrive in a range of different growing climates, including plants suited to grow in cold weather and plants that are resilient to region-specific fungi.

Joint Venture with Rock Creek Farms of British Columbia

Pac Roots recently entered a definitive investment agreement with Rock Creek Farms, a reputable agricultural enterprise, for a 100-acre commercial hemp operation in Rock Creek, British Columbia. The growing space is located in the highly lucrative farming area known as the ‘Golden Mile’ in the South Okanagan Valley of British Columbia. (http://nnw.fm/Gbf9I).

Under the agreement, the two companies have formed an outdoor premium hemp joint venture company to which Pac Roots is providing an aggregate of $450,000 in capital and Rock Creek Farms is contributing two commercial leases for 100+ acres of growing space, along with cultivation licenses, agricultural infrastructure and equipment, consulting services, intellectual property relating to hemp operations and proprietary biomass storage methods. Pac Roots holds a 60 percent interest in the project.

About 127,500 premium hemp CBD seedlings were planted across 100 acres as of early July 2020. The joint venture is planting a premium grade CBD hemp variety utilizing the rich native soil and both traditional and custom farming techniques.

“Our operational partners at Rock Creek Farms bring decades of generational farming expertise in one of Canada’s pre-eminent growing regions,” Pac Roots President and CEO Patrick Elliott said in a news release detailing the venture. “It will be an exciting outdoor growing season for the joint venture as we anticipate a successful harvest in the fall.”

Infinite Development Possibilities at Fraser Valley Property in British Columbia

In mid-July 2020, the company initiated a share purchase agreement with 1088070 BC. LTD. (“1088”) and its shareholders for the acquisition of all issued and outstanding shares of 1088 (http://nnw.fm/xlpw7). Notably, 1088 owns and controls 250 acres of land spread over nine parcels in the Fraser Valley Regional District.

The Fraser Valley Regional District is one of the most productive and intensively farmed areas of Canada, offering access to high-quality soil, favorable climate, water and a local market of 2.5 million people. Agriculture in this region yields an annual economic value of more than $3 billion.

The closing date for the transaction is slated for September 4, 2020, after a 51-day due diligence period. According to Elliott, the addition of such a significant package of land is a major step for Pac Roots.

“This land has no zoning restrictions and is not situated within the agricultural land reserve, which provides for infinite development possibilities,” Elliott added in a July 2020 news release.

Board of Directors member Chad Clelland also welcomed the acquisition, adding that between Fraser Valley and Rock Creek – both of them among the most productive agricultural regions in Canada – Pac Roots is very well positioned for production and the future development of its hemp and cannabis infrastructure.

The RAD Americas Genetic Program – Research and Development in Americas Genetic Program

Pac Roots intends to deploy a global R&D program focused on rigorously testing elite strains in various rich agricultural regions throughout the Americas, with a goal of mass selection to achieve the utmost environmental resilience while achieving notable quality and yields. From seed to software, collection data, proprietary techniques and custom nutrient formulas, Pac Roots and Phenome will provide the specific knowledge to cultivators in different climates in order to achieve optimal yields for THC, CBD, CBG and other unique cannabinoids. R&D from global testing programs situated throughout the Americas will allow the partnership to deploy and stress test a range of suitable cultivars in the world’s lowest cost outdoor growing regions.

The company expects an industry shift in 2020 from the COVID-19 global pandemic. The ‘new normal’ will bring more focus on efficiencies and optimal yields to deliver a cost effective, high quality product to the end user. There has been much to be learnt from the inefficiencies in the cannabis industry in recent years, which have been detrimental to the credibility of the sector. Pac Roots is well positioned to enter the scene and take advantage of the deficiencies, reinforcing the notion that genetics and flawless growing techniques are paramount to success. Genetics and systems innovation may be the most overlooked components when comparing cannabis to other established agricultural crops. Pac Roots plans to invest into cannabis R&D to ensure a solid foundation is built that will be used by cannabis farmers worldwide.

Through its RAD Americas Development and Innovation, Pac Roots is focused on:

  • Deploying one of the largest live genetic libraries in Canada, diversified for high yield output and unique climates
  • Continued stress testing for indoor, high yield, THC and medicinal genetics
  • Continued stress testing for outdoor, high yield, THC and medicinal genetics
  • Exotic, genetic cloning for the luxury, high margin, cannabis flower market
  • Psychoactive/medicinal ratio testing for effect and
  • Unique Cannabinoid and terpene elevation and isolation.

Through its RAD Americas Field Testing System, the company is focused on:

  • Global testing in different microclimates to assess genetic and complete systems for optimal yields
  • Data collection, testing and optimization to prove process for commercial implementation and
  • High quality yield testing for THC, CBD, CBG and other unique medicinal cannabinoids.

Lake Country Cultivation Facility near Kelowna, British Columbia

Pac Roots is in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through its line of high-grade cultivars. Pac Roots plans to submit a video evidence package of the facility build under Health Canada’s Cannabis Tracking and Licensing System, and the company expects to acquire its cultivation license in the fourth quarter of 2020.

Lake Country is a municipality located just outside of Kelowna in the Okanagan region of British Columbia. For decades, the region’s favorable growing climate has made it a hub for cannabis cultivation. As the Canadian legal cannabis industry ramps up, the Okanagan region is attracting attention from dozens of cannabis companies, including some of the industry’s biggest names. The region’s strong agricultural history has left it rich with experienced agricultural workers and an abundance of Agricultural Land Reserve (ALR) property.

Management Team

Patrick Elliott, MSC, MBA, President and CEO of Pac Roots Cannabis, is also the President & CEO of Lexore Capital Corp., a private resource and cannabis investment company, as well as Phenome One Corp., a full-service cannabis farming company focused on elite strain selective breeding. Elliott brings over 15 years of corporate finance, mineral exploration and financial markets experience to the Pac Roots team. He is a graduate of the University of Western Ontario in geology and holds an MSc. in mineral economics and an MBA from Curtin University of Technology in Perth, Australia. Elliott specializes in economic resource evaluation, financial modeling, CAPEX estimation, corporate development and finance. Combined with his technical knowledge, Elliott has a wealth of contacts in the financial sector.

Marc Geen, Founder and Strategic Operations Advisor, is a fourth-generation British Columbia farmer who has been active in the legal medical marijuana industry for more than 10 years – consulting on, complying with, and participating in the MMAR, MMPR and ACMPR programs. Prior to co-founding Speakeasy Cannabis Club Ltd., Geen spent 14 years as Head of Operations for Kettle Mountain Ginseng Ltd., one of North America’s largest ginseng producers. With the experience gleaned from a long career in large scale commercial farming, Geen has been able to apply many cost-effective farming practices to the outdoor, indoor and greenhouse cultivation of cannabis. Geen is also the co-creator of a full line of cannabis extract products designed under ACMPR regulations.

Matt McGill, Director, has a strong background in both commercial and residential real estate and has played a major role in many development projects. McGill, through McGill Realty, has established a tremendous commercial and residential outfit servicing British Columbia’s Fraser Valley and the lower mainland. McGill is skilled at crafting strategic financing options for corporations and has a substantial network of retail and institutional clients.

Chad Clelland, Director, has experience in the sector dating back to 2009, when he purchased Medicalmarijuana.ca, which became an information portal for thousands of patients, doctors and growers. Through this company, he and his team have helped thousands of Canadians find legal, safe medication. His team also consulted, designed and submitted dozens of applications to the government under the MMPR, ACMPR and Cannabis Act. In 2011, Clelland co-founded Greenleaf Medical Clinic, which is now recognized as a training facility by the University of British Columbia and offers preceptorships to physicians, nurse practitioners and pharmacists. He also co-founded Folium Life Science in 2013, an approved Canadian Licensed Producer. His roles in these organizations have included Chief Operating Officer, head of security, alternate master grower and alternate responsible person in charge.

Josh Bromley, Senior Cultivation Strategist, is a second-generation farmer with over two decades of experience farming, breeding, cultivating and selecting unique cultivars for the medical community. He is an expert in plant science and possesses a comprehensive knowledge of cultivars and a mastery of medicinal implementation. Bromley has developed proprietary farming systems, as well as low cost/high output nutrient systems. Through thoughtful design and engineering, he has been able to consistently show improvements in crop yields, pathogen resiliency and quality.

Pac Roots Cannabis Corp. (PACR), closed Tuesday's trading session at $0.20, off by 9.09%, on 2,499 volume with 2 trades. The average volume for the last 3 months is 15,306 and the stock's 52-week low/high is $0.11/$0.72.

Recent News

Siyata Mobile Inc. (NASDAQ: SYTA) (TSXV: SIM)

The QualityStocks Daily Newsletter would like to spotlight Siyata Mobile Inc. (SYTA).

Siyata Mobile (NASDAQ: SYTA, SYTAW) (TSX.V: SIM), a leading global developer and provider of Push-to-Talk Over Cellular (“PTT/PoC”) systems for enterprise customers, has appointed a new U.S. vice president of sales for the company’s Uniden(r) cellular signal booster portfolio. LaRue Martz will take over the position effective immediately. An experienced sales exec, Martz has worked in various capacities in several leading telecommunications companies, including stints at Nextivity, Samsung Wireless and Huawei. To view the full press release, visit: https://nnw.fm/xs5uN

Siyata Mobile Inc. (NASDAQ: SYTA) (TSXV: SIM) is a leading global developer and provider of Push-to-Talk Over Cellular (“PTT/PoC”) systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world’s first 3G connected vehicle device as well as the world’s first 4G/LTE vehicle-mounted smartphone for First Responders and commercial fleets and vehicles, thereby creating a new category in the cellular device market with a dedicated smartphone tailor-made for the commercial vehicle market.

Siyata is headquartered in Montréal, Québec, Canada.

Product Portfolio

Siyata’s suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company’s flagship product, the Uniden UV350, is the world’s first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada’s largest LTE network and PTT community, as well as AT&T in the U.S. Further expanding its availability, Siyata is completing network approval with another U.S. Tier 1 operator to launch the UV350 in Q3 2019.

Management Team

CEO and Chairman Marc Seelenfreund is the founder of Siyata. He is also the founder of Siyata’s parent company, Accel Telecom, an Israel-based company that specializes in importing and distributing innovative cellular and IP devices to fixed line operators and mobile providers within Israel. Prior to establishing Accel, Seelenfreund was a vice president at Sunrise Corporation in New York where he focused on financing publicly traded technology companies. Seelenfreund has a law degree from Bar Ilan University, is a board member at Israel’s leading private university, and has served as an officer in the Israel Defense Forces.

Glenn Kennedy, vice president of sales, has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Kennedy managed sales nationally for Motorola Canada, HTC Communications Canada, and Sonim Technologies. He holds a bachelor’s degree in honors business administration from the Richard Ivey School of Business at the University of Western Ontario.

CFO Gerald Bernstein, a professional chartered accountant, has spent 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. He holds a bachelor’s degree of commerce as well as a graduate diploma in public accountancy from McGill University. Bernstein has been a member of the Canadian Institute of Chartered Accountants since 1987.

Gidi Bracha, vice president of technology, has served in this position since 2011 and spearheaded the development of both the Truckfone, Voyager and UV350. Bracha served in various key positions at Cellcom, Israel’s leading cellular provider, including head of car mobility products and director of type approvals. Bracha served as an engineer technician in the Anti-Aircraft division of the Air Force in the Israel Defense Forces and holds a bachelor’s degree in engineering and business management from the University of Derby.

Siyata Mobile Inc. (SYTA), closed Tuesday's trading session at $5.00, up 5.93%, on 69,899 volume with 315 trades. The average volume for the last 3 months is 96,050 and the stock's 52-week low/high is $3.90/$5.40.

Recent News

Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B)

The QualityStocks Daily Newsletter would like to spotlight Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B).

Bullfrog Gold (OTCQB: BFGC) (CSE: BFG) (FSE: 11B), a corporation engaged in the acquisition, exploration and development of gold and silver properties in the United States, announced that it has signed definitive agreements with Augusta Investments Inc. ("Augusta") and certain Barrick Gold Corporation subsidiaries ("Barrick"). To view the full press release, visit http://ibn.fm/lpUei

Bullfrog Gold Corp. (the “Company”) (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) is a Delaware corporation engaged in the acquisition, exploration and development of gold and silver properties in the United States. The Company controls strategic lands with established 43-101 compliant resources in one of the most exciting gold exploration areas in the United States. The Bullfrog Gold Project (“Project”) includes a lease/option on much of the lands where Barrick Bullfrog Inc., a subsidiary of Barrick Gold Corp., produced more than 2.3 million ounces of gold and 2.49 million ounces of silver from 1989 to 1999. The Project is located within the prolific Walker Trend about 125 miles northwest of Las Vegas, Nevada.

Project Highlights

  • The Company initially acquired 79 unpatented claims and two patents in mid-2011 and has since staked, leased, optioned, or purchased lands that now total 5,250 acres. Via a 2015 lease/option with Barrick, the Project includes the northern one-third of the Bullfrog deposit where most of the current resources in the Bullfrog mine area occur, along with their interest in the Montgomery-Shoshone deposit which gave the Company 100% control.
  • In mid-2017, a NI 43-101-compliant report by independent mining consultancy Tetra Tech Inc. estimated measured and indicated (“M&I”) resources of 624,000 ounces of gold and 1.73 million ounces of silver at average grades of 0.70 g/t and 1.93 g/t, respectively. The expansion plans of these two pits were based on a $1200 gold price, use of heap leach processing, and also included 110,000 ounces of inferred gold resources averaging 1.20 g/t. Barrick used conventional milling to process an average gold grade of 3 g/t.
  • The established resources and exploration potential of the Project are strongly supported by a large data base obtained from Barrick, including detailed information on 155 miles of drilling in 1,262 holes in the Bullfrog mine area.

Gold Rush in the Bullfrog Territory

The area around Beatty, Nevada has now attracted AngloGold Ashanti, Kinross Gold, Corvus Gold, Coeur Mining as well as the Company and Waterton. In this regard, Northern Empire Resources Corp’s property located a few miles east of the Project was acquired by Coeur Mining in October 2018 for C$117 million, implying a valuation of C$134/oz of inferred resources. As of today, the Company is trading at a significant discount to the valuation at which Northern Empire was purchased (http://nnw.fm/9NaaN), thereby highlighting the Company’s value proposition for investors.

Bullfrog Gold Corp. is focused on enhancing shareholder returns by concurrently advancing Project development and performing exploration drilling programs on several targets identified by the Company.

Secured Financing for 2020 Operations

Bullfrog Gold Corp. raised C$2 million in January 2020 through a private placement of shares priced at C$0.13/share plus a one-half warrant exercisable within two years at C$0.20 on a full warrant basis. The raise was carried out primarily to fund a drill program that started on May 1 (http://nnw.fm/6nZ0m), and was completed on June 6, 2020. Results from drilling 12,520 feet in 25 holes will be released in the coming weeks. The Company subsequently intends to conduct a preliminary financial analysis and complete further drill programs to advance the Project and add value. The financing was subscribed by several influential shareholders, including a former director of Northern Empire, who handled the sale of the company to Coeur Mining, and Eros Resources, the management of which has been involved with several high-profile mining projects and sales in the past.

Gold Prices estimated to average $1,800/oz in 2021

Gold prices have been on a remarkable run in 2020, rising by $245/oz to $1,760 prior to peaking in early May. Global central banks carried out 144 interest rate cuts thus far in 2020, reducing their rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the COVID-19 pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures prompted Credit Suisse to recently hike their gold price forecasts for the full year to $1,701/oz (from $1,570 previously), while the outlook for 2021 has been raised to $1,800/oz (versus $1,600 previously) (http://nnw.fm/Iqg0X).

Management Team

David Beling, CEO, President and Director
David Beling is a Registered Professional Mining Engineer with 55 years of diverse experience in areas such as engineering, development, permitting, construction, financing and management of mines and plants and the building and growth of several corporations. His initial employment included 14 years with Phelps Dodge, Union Oil, Fluor, United Technologies, and Westinghouse, followed by 41 years of senior management and consulting with 25+ U.S. and Canadian mining companies. In 2006-2007, he spearheaded an IPO, successfully drove equity raises totaling C$112 million and grew that Company’s market capitalization to $460 million. Beling has served on 14 boards since 1981, including three mining companies distinguished by the TSX Venture Exchange as top-10 performers.

Alan Lindsay, Chairman of the Board
Alan Lindsay is an entrepreneur and businessman who has founded seven companies within the mining and pharmaceutical industries, including Anatolia Minerals Development Ltd., Uranium Energy Corp., Oroperu Mineral, Strategic American Oil and AZCO Mining. Lindsay also developed the strategic vision for the 2011 acquisition and placement of the Project from NPX Metals into Bullfrog Gold Corp.

Kjeld Thygesen, Director
Kjeld is a graduate of the University of Natal in South Africa and has 48 years of experience as a resource analyst and fund manager. In 1972, he joined James Capel and Co. in London as part of its highly rated gold and mining research team before subsequently becoming manager of N. M. Rothschild & Sons’ commodities and Natural Resources Department in 1979. In 1987, he became an executive director of N. M. Rothschild International Asset Management Ltd., before co-founding Lion Resource Management Ltd., a specialist investment manager in the mining and natural resources sector, in 1989. Thygesen has been a director of Ivanhoe Mines Ltd. since 2001 and served as investment director for Resources Investment Trust PLC from 2002 to 2006.

Tyler Minnick, CFO and Director of Administration & Finance
A registered member of the Colorado Society of Certified Public Accountants with over 24 years of experience within the fields of accounting, auditing, and administrative services. Minnick has been engaged with the Company since mid-2011 and previously worked in the finance department of MDC Holdings/Richmond American Homes, one of the largest residential construction companies in the United States.

Bullfrog Gold Corp. (OTCQB: BFGC), closed Tuesday's trading session at $0.24, up 5.8901%, on 516,288 volume with 112 trades. The average volume for the last 3 months is 317,173 and the stock's 52-week low/high is $0.047449998/$0.27000001.

Recent News

Grey Cloak Tech Inc. (GRCK)

The QualityStocks Daily Newsletter would like to spotlight Grey Cloak Tech Inc. (GRCK).

Grey Cloak Tech (OTC: GRCK) (soon to be Healthy Extracts Inc.), together with its growing portfolio of wholly owned subsidiaries, is focused on advancing market positions in the broader health industry through the unique assets and operations of its science-based BergaMet North America and Ultimate Brain Nutrients (“UBN”) subsidiaries. To view the full article, visit: https://nnw.fm/yzont.

Grey Cloak Tech Inc. (GRCK), through its growing portfolio of wholly owned subsidiaries, is engaged in the proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. The company’s focus is to advance its market positions in the broader health industry through the unique assets and operations of its science-based BergaMet North America and Ultimate Brain Nutrients (“UBN”) subsidiaries and to offer better lifestyles through superior health technology.

BergaMet North America

BergaMet NA is engaged in the sale and distribution of a full line of proprietary product formulations derived from the rare Citrus Bergamot SuperFruit™ called “bergamot.” Bergamot is native to Southern Italy and is naturally sourced and uniquely loaded with various antioxidant polyphenols. Thanks to this composition, bergamot supports and promotes overall wellness specific to cholesterol, cardiovascular and metabolic health with no known side effects.

BergaMet NA is the only Citrus Bergamot SuperFruit™ heart health supplement backed by 17 clinical studies. The BergaMet brand supplement boasts the highest quality and concentration of polyphenols and flavonoids available anywhere in the world. It is also the only bergamot supplement approved by the prestigious Accademia del Bergamotto of Italy. BergaMet NA is the only company authorized to manufacture, distribute and sell these products in the United States, Canada and Mexico.

Consumers are including the Citrus Bergamot SuperFruit™ in their everyday personal health programs. The clinically proven antioxidant provides benefits to tens of thousands of people daily.

The company’s line of products can be found at www.bergametna.com, through Amazon, other online retailers and in doctors’ offices throughout the United States.

The BergaMet Advantage

BergaMet has been studied in 17 published clinical trials which reported results of lower LDL cholesterol, higher HDL cholesterol, lower triglycerides, lower blood pressure, lower blood glucose, increased arterial function, improved liver function and is effective as a complement to statin use.

Cardiovascular disease is the number one cause of death in the U.S. and worldwide, claiming nearly 18 million lives each year accounting for 31% of all global deaths. In the U.S., statins are one of the most commonly prescribed medicines for cardiovascular disease. The Centers for Disease Control estimates that 28% of American women and men over the age of 40 take a statin to lower the amount of cholesterol in the blood.

Taking aim at this market for cardiovascular care, BergaMet NA continues to advance the awareness of its medical-grade supplements and separate its formulation from competitors.

BergaMet NA products contain 47% BPF (bergamot polyphenolic fraction), while its closest competitors have only 38%. The company’s increased dosages (600-675mg vs 500mg) and 47% BPF are clinically proven to be more effective in improving heart health and metabolic syndrome.

BergaMet Citrus Bergamot SuperFruit™ supplements:

  • Support healthy immune systems with powerful antioxidants and proprietary formulations.
  • Reduce cholesterol and support healthy glucose and blood pressure levels.
  • Are fully organic, vegan-friendly and dairy, gluten, soy and GMO-free.
  • Contain five key unique flavonoids that make up the most powerful 47% BPF (bergamot polyphenolic fraction) in the world, providing superior results compared to their competitors.
  • Have been clinically shown to increase arterial elasticity while reducing arterial and muscle inflammation.

Ultimate Brain Nutrients

Grey Cloak’s Ultimate Brain Nutrients (“UBN”) subsidiary is a science-based company that develops unique, plant-based superior health technology neuro-products that improve brain health, including memory, cognition, focus and neuro-energy.

UBN’s KETONOMICS® proprietary formulations — targeting brain activity, focus, headache and cognitive behavior — provide multiple intellectual property license opportunities for monetizing the company’s portfolio.

License opportunities include multiple beverage formats, individual products, proprietary mixtures and other food platforms.

UBN has five unique formulation patents — one issued and four pending — targeting brain activity, focus, headache and cognitive behavior.

The UBN Advantage

UBN’s all-natural, sugar-free and caffeine-free proprietary formulations are the result of 20 years of scientific research and are positioned to provide consumer neuro-products that are natural brain solutions. UBN has filed for approval to the U.S. Food and Drug Administration (FDA) to make a Qualified Health Claim for its migraine formulation, tapping into consumer demands for healthy beverages that contribute to brain health, overall well-being and performance.

Over 50 million Americans consume unhealthy energy shots and drinks each day, while the neuro/energy market generates over $10 billion per year in revenue. Within this growing market, UBN is advancing its position to meet rising consumer demand for healthy, science-based options. The company’s KETONOMICS® proprietary formulations have been proven to naturally elevate brain energy and function, including memory, cognition and focus.

UBN’s KETONOMICS® supplementation has also been studied in sports physiology, with specific regard to its potential benefits for competitive performance and endurance.

Grey Cloak Executive Team

Kevin “Duke” Pitts, Director, President and Chief Operating Officer

  • Started and built from the ground up two multi-million-dollar businesses, one of which grew into a Top 100 retailers in the U.S.
  • Unique management skills led to the development of successful teams for 35 years
  • Pioneered direct marketing for a Fortune 200 company, creating a 20% increase in targeted incremental sales
  • Founded Einstein’s Hemp, which developed and brought to market one of the only odorless and tasteless water-soluble CBD products in the world
  • Developed and implemented digital/guerrilla marketing strategies for public and private companies focused on long-term brand position and acquisition efforts
  • Specialized in customer relationship management (CRM) tools for creating the best customer experiences
  • Worked in publicly traded industries for 10 years, overseeing up to $20 million in annual marketing budgets

William “Bill” Bossung, Director, Chief Financial Officer

  • 35 years of diverse experience in corporate finance, insurance and accounting
  • 20 years of experience with IPOs focusing on audits, FINRA and SEC regulations
  • Specializes in the formation of capital raising over $100 million, recently raising $12 million for Splash Beverage
  • Specializes in upgrading penny stocks companies to the NYSE or Nasdaq
  • Involved in 30+ companies transitioning from private to public identities
  • Founded several companies, including BCF Technology Inc., which sold to Vertafore; managing partner at Bishop Equity Partners LLC; director at Splash Beverage Group; and director of finance at Chadmoore Wireless, where he licensed channels to Nextel for $162 million

Bill Croyle, Director, Private Investor and Accomplished Senior Executive

  • More than 40 years of success in the IT, energy, manufacturing, telecommunications, venture capital and finance industries
  • Broad expertise includes negotiating mergers and acquisitions, as well as service and delivery contracts
  • Formerly was a founder, owner or executive of EnTX Group; Impact Legacy Partners; FB Oilfield Special Tools; and Western Energy Advisors

Dr. Gerald Haase, Chief Medical Officer

  • Clinical professor of surgery at the University of Colorado, School of Medicine
  • Actively involved in medical research and clinical trials for 35 years
  • Received U-10 grant funding from the National Institutes of Health cooperative group clinical trials program, as well as U.S. Congressional funding for Cooperative Research and Development Agreements with the Department of Defense and NASA
  • Was chairman of the Department of Pediatric Surgery at Children’s Hospital Colorado; consultant surgeon to the Department of the Army; vice-chairman of the Children’s Cancer Group, a cooperative research consortium of the National Cancer Institute; on the National Board of Directors of the American Cancer Society; a senior member of the Commission on Cancer of the American College of Surgeons; and a member of the editorial board of The Annals of Surgical Oncology
  • Has published 180 scientific papers and is the inventor or co-inventor of 12 issued U.S. patents for micronutrient and phytonutrient therapy, with five pending patents
  • Recipient of clinical research grants and contracts funded at a several million-dollar cumulative level
  • Is an editorial reviewer for medical journals and a member of numerous professional societies, including the American Association for Cancer Research, International College of Surgeons, American Academy of Pediatrics, New York Academy of Sciences and American College of Physician Executives

Grey Cloak Tech Inc. (GRCK), closed Tuesday's trading session at $0.0629, up 36.7391%, on 29,052 volume with 6 trades. The average volume for the last 3 months is 16,387 and the stock's 52-week low/high is $0.019999999/$0.104999996.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.